<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349906</url>
  </required_header>
  <id_info>
    <org_study_id>MC-FludT.16/NM</org_study_id>
    <nct_id>NCT02349906</nct_id>
  </id_info>
  <brief_title>Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases</brief_title>
  <official_title>Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Venn Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to describe the safety and efficacy of intravenous (i.v.) Treosulfan&#xD;
      compared to the conventional (myeloablative) dose of i.v. Busulfan, each administered as part&#xD;
      of a standardised Fludarabine-containing conditioning regimen and to contribute to a PK model&#xD;
      which permits - in conjunction with data comparing Treosulfan and Busulfan in adults with&#xD;
      malignant diseases - to extend the use of Treosulfan in the paediatric population by&#xD;
      extrapolating efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective clinical phase II protocol MC-FludT.16/NM is to be conducted to verify safety&#xD;
      and efficacy of Treosulfan-based conditioning compared to Busulfan-based conditioning in&#xD;
      paediatric patients. Based on the given clinical experience with either Treosulfan-based or&#xD;
      Busulfan-based conditioning in combination with Fludarabine no increased risk for graft&#xD;
      failure is expected in paediatric patients. A potential benefit for study patients is&#xD;
      expected with respect to a probably low non-haematological toxicity of treatment compared to&#xD;
      myeloablative TBI-based conditioning or high-dose Busulfan-based conditioning in combination&#xD;
      with Cyclophosphamide.&#xD;
&#xD;
      However, the allogeneic HSCT procedure itself potentially involves serious risks with regard&#xD;
      to severe or life-threatening conditions like graft versus host disease (GvHD) and/or&#xD;
      infectious complications as well as graft failure.&#xD;
&#xD;
      In summary, the primary goal of this study is to evaluate the Treosulfan-based myeloablative&#xD;
      conditioning regimen as an alternative in children and to contribute to the current PK model&#xD;
      for Treosulfan to be able to finally give age (or body surface area [BSA]) dependent dose&#xD;
      recommendations. The treatment regimens given in the protocol MC-FludT.16/NM are based on&#xD;
      sufficient clinical safety and efficacy data. Considering the vital indication for allogeneic&#xD;
      HSCT of the selected patient population, the risk-benefit assessment seems to be in favour of&#xD;
      the study conduct.&#xD;
&#xD;
      Moreover, planned interim analyses will ensure the early identification of unexpected risks.&#xD;
      Therefore, the conduct of the protocol MC-FludT.16/NM is considered reasonably justified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Actual">May 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative evaluation of freedom from transplant (treatment)-related mortality (TRM), defined as death from any transplant-related cause from the day of first administration of study medication (day -7) until day +100 after HSCT.</measure>
    <time_frame>day -7 to day +100</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Primary Immunodeficiencies</condition>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Haemoglobinopathies</condition>
  <condition>Bone Marrow Failure Syndromes</condition>
  <arm_group>
    <arm_group_label>Treosulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.&#xD;
The dose has to be calculated as follows:&#xD;
If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.&#xD;
If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.&#xD;
If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <arm_group_label>Treosulfan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busilvex</intervention_name>
    <arm_group_label>Busulfan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-malignant disease indicated for first myeloablative allogeneic HSCT, including&#xD;
             inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies and bone&#xD;
             marrow failure syndromes.&#xD;
&#xD;
          2. First allogeneic HSCT.&#xD;
&#xD;
          3. Available matched sibling donor (MSD), matched family donor (MFD) or matched unrelated&#xD;
             donor (MUD). For bone marrow (BM) and peripheral blood (PB) match is defined as at&#xD;
             least 9/10 allele matches after four digit typing in human leucocyte antigen (HLA)-A,&#xD;
             -B, -C, -DRB1 and DQB1 antigens. For umbilical cord blood (UCB) match is defined as at&#xD;
             least 5/6 matches after two digit typing in HLA-A and -B and four digit typing in DRB1&#xD;
             antigens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Second or later HSCT.&#xD;
&#xD;
          2. HSCT from mismatched donor (less than 9/10 BM/peripheral blood stem cells (PBSC) or&#xD;
             less than 5/6 matched cord donor).&#xD;
&#xD;
          3. Preterm newborn infants (&lt;37 weeks gestational age) and term newborn infants aged 0 -&#xD;
             27 days at time of registration.&#xD;
&#xD;
          4. Obese paediatric patients with body mass index weight (kg)/[height (m)]² &gt; 30 kg/m².&#xD;
&#xD;
          5. Diagnosis of Fanconi anaemia and other chromosomal breakage disorders,&#xD;
             radiosensitivity disorders (deoxyribonucleic acid (DNA) Ligase 4, Cernunnos- X-ray&#xD;
             repair cross-complementing protein 4 (XRCC4) like factor (XLF), Nijmegen Breakage&#xD;
             Syndrome (NBS)) and Dyskeratosis Congenita.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Walter Sykora, MD and Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Motol, Dep. of Paediatric Haematology and Oncology</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Oncology &amp; Hematology, Charite Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Essen Pediatric stem cell transplantation</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical University, Dep. of Paediatrics, Paediatric Haematology and Oncology</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Jena, Department of Pediatrics</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm, University Hospital, Clinic for Children and Adolescents</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Oncoematologia Pediatrica Ospedale Pediatrico Microcitemico &quot;Antonio Cao&quot; A.O. Brotzu</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia ed Oncologia Pediatrica con TMO AOU Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reparto Trapianti Midollo Osseo Clinica Pediatrica Universitaria Fondazione MBBM-Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Oncoematologia Pediatrica Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia Pediatrica A.O. di Perugia Ospedale S. Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncoematologia Pediatrica Azienda Ospedaliero Universitaria Pisana Ospedale S. Chiara</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesu Roma</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Oncoematologia Pediatrica Policlinico &quot;G.B. Rossi&quot; - AOUI Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki im. dr Antoniego Jurasza</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dzieciecy w Krakowie</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dzieciecy Szpital Kliniczny im. A. Gebali w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University, Department of Pediatric Hematology/Oncology and BMT</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-malignant diseases, allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Bone Marrow Failure Disorders</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

